RxDoctor Payments Data

Nathan Holtzberg, MD

Pain Medicine · Manasquan, NJNPI 1295714715

Payments from drug & device makers

$3,149in general payments, 2019–2025

Across 61 payments — averaging $51.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Curonix LLC$602
  • Nevro Corp.$427
  • Foundation Fusion Solutions, LLC$269
  • Medtronic$226
  • Vertos Medical, Inc.$203
  • plus $359 from 7 others

What the payments were for

  • Travel & lodging$84927%
  • Food & beverage$2,28873%
  • Entertainment$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,149 in reported general payments places this provider in the 65th percentile of 256 pain medicine providers in New Jersey.

See all pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$65,282
Medicare patients
315
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen386$15,648
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen393$13,020
Xtampza ErOxycodone Myristate30$12,993
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$3,591
Fentanyl29$2,459
Oxycodone Hcl154$2,414
Morphine Sulfate ErMorphine Sulfate100$2,400
Buprenorphine18$2,343
Pregabalin80$1,578
Gabapentin114$1,383
Tramadol Hcl110$1,147
Tramadol Hcl ErTramadol Hcl14$1,047
Buprenorphine Hcl16$619
Cyclobenzaprine Hcl42$514
Celecoxib23$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$45$12,99330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 256 pain medicine providers in New Jersey.

Other pain medicine in Manasquan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →